Travis, Ruth CPerez-Cornago, AuroraAppleby, Paul NAlbanes, DemetriusJoshu, Corinne ELutsey, Pamela LMondul, Alison MPlatz, Elizabeth AWeinstein, Stephanie JLayne, Tracy MHelzlsouer, Kathy JVisvanathan, KalaPalli, DomenicoPeeters, Petra HBueno-de-Mesquita, BasTrichopoulou, AntoniaGunter, Marc JTsilidis, Konstantinos KSánchez, Maria-JoseOlsen, AnjaBrenner, HermannSchöttker, BenPerna, LauraHolleczek, BerndKnekt, PaulRissanen, HarriYeap, Bu BFlicker, LeonAlmeida, Osvaldo PWong, Yuen Yee ElizabethChan, June MGiovannucci, Edward LStampfer, Meir JUrsin, GiskeGislefoss, Randi EBjørge, ToneMeyer, Haakon EBlomhoff, RuneTsugane, ShoichiroSawada, NorieEnglish, Dallas REyles, Darryl WHeath, Alicia KWilliamson, Elizabeth JManjer, JonasMalm, JohanAlmquist, MartinMarchand, Loic LeHaiman, Christopher AWilkens, Lynne RSchenk, Jeannette MTangen, Cathy MBlack, AmandaCook, Michael BHuang, Wen-YiZiegler, Regina GMartin, Richard MHamdy, Freddie CDonovan, Jenny LNeal, David ETouvier, MathildeHercberg, SergeGalan, PilarDeschasaux, MélanieKey, Timothy JAllen, Naomi E2019-02-182019-02-182019-01-011538-74453042505810.1158/0008-5472.CAN-18-2318http://hdl.handle.net/10029/622787: Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)eninfo:eu-repo/semantics/closedAccessArticleCancer Res 2019; 79(1):274-85